Financhill
Sell
36

HUM Quote, Financials, Valuation and Earnings

Last price:
$241.67
Seasonality move :
4.85%
Day range:
$229.23 - $236.91
52-week range:
$212.45 - $406.46
Dividend yield:
1.5%
P/E ratio:
16.65x
P/S ratio:
0.24x
P/B ratio:
1.60x
Volume:
2.3M
Avg. volume:
1.8M
1-year change:
-34.42%
Market cap:
$28.4B
Revenue:
$117.8B
EPS (TTM):
$14.14

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
HUM
Humana
$32.2B $10.07 7.73% 6.96% $298.53
ADUS
Addus HomeCare
$339.9M $1.33 20.51% 33.48% $136.45
AMED
Amedisys
$596.5M $1.11 4.11% 40.38% $97.38
CVS
CVS Health
$93.4B $1.67 3.98% 3.13% $79.49
OPCH
Option Care Health
$1.3B $0.35 10.25% 32.25% $38.56
OPRX
OptimizeRx
$18.7M -$0.12 18.36% -91.67% $15.67
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
HUM
Humana
$235.39 $298.53 $28.4B 16.65x $0.89 1.5% 0.24x
ADUS
Addus HomeCare
$114.44 $136.45 $2.1B 25.83x $0.00 0% 1.69x
AMED
Amedisys
$97.34 $97.38 $3.2B 35.92x $0.00 0% 1.36x
CVS
CVS Health
$67.71 $79.49 $85.7B 16.16x $0.67 3.93% 0.23x
OPCH
Option Care Health
$31.82 $38.56 $5.2B 25.66x $0.00 0% 1.05x
OPRX
OptimizeRx
$13.77 $15.67 $254.7M -- $0.00 0% 2.68x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
HUM
Humana
42.84% 1.190 41.58% 1.50x
ADUS
Addus HomeCare
16.64% 0.542 10.92% 1.61x
AMED
Amedisys
23.6% -0.136 12.01% 1.23x
CVS
CVS Health
45.69% 0.768 75.52% 0.59x
OPCH
Option Care Health
45.12% 0.716 19.41% 0.91x
OPRX
OptimizeRx
21.84% -1.569 20.29% 2.69x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
HUM
Humana
-- -- 5.74% 10.08% 5.76% $236M
ADUS
Addus HomeCare
$107.7M $30.5M 7.78% 8.66% 9.18% $17.1M
AMED
Amedisys
$260.7M $60.1M 5.72% 7.55% 16.41% -$5.1M
CVS
CVS Health
$14.4B $3.4B 3.75% 7% 3.6% $3.8B
OPCH
Option Care Health
$263.1M $79.2M 8.53% 15.22% 5.76% -$16.6M
OPRX
OptimizeRx
$13.3M -$2.1M -10.09% -13.03% -9.06% $3.8M

Humana vs. Competitors

  • Which has Higher Returns HUM or ADUS?

    Addus HomeCare has a net margin of 3.87% compared to Humana's net margin of 6.29%. Humana's return on equity of 10.08% beat Addus HomeCare's return on equity of 8.66%.

    Company Gross Margin Earnings Per Share Invested Capital
    HUM
    Humana
    -- $10.30 $31.1B
    ADUS
    Addus HomeCare
    31.89% $1.16 $1.2B
  • What do Analysts Say About HUM or ADUS?

    Humana has a consensus price target of $298.53, signalling upside risk potential of 26.82%. On the other hand Addus HomeCare has an analysts' consensus of $136.45 which suggests that it could grow by 19.24%. Given that Humana has higher upside potential than Addus HomeCare, analysts believe Humana is more attractive than Addus HomeCare.

    Company Buy Ratings Hold Ratings Sell Ratings
    HUM
    Humana
    6 17 0
    ADUS
    Addus HomeCare
    8 0 0
  • Is HUM or ADUS More Risky?

    Humana has a beta of 0.427, which suggesting that the stock is 57.339% less volatile than S&P 500. In comparison Addus HomeCare has a beta of 0.806, suggesting its less volatile than the S&P 500 by 19.425%.

  • Which is a Better Dividend Stock HUM or ADUS?

    Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.5%. Addus HomeCare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humana pays 35.71% of its earnings as a dividend. Addus HomeCare pays out -- of its earnings as a dividend. Humana's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios HUM or ADUS?

    Humana quarterly revenues are $32.1B, which are larger than Addus HomeCare quarterly revenues of $337.7M. Humana's net income of $1.2B is higher than Addus HomeCare's net income of $21.2M. Notably, Humana's price-to-earnings ratio is 16.65x while Addus HomeCare's PE ratio is 25.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.24x versus 1.69x for Addus HomeCare. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HUM
    Humana
    0.24x 16.65x $32.1B $1.2B
    ADUS
    Addus HomeCare
    1.69x 25.83x $337.7M $21.2M
  • Which has Higher Returns HUM or AMED?

    Amedisys has a net margin of 3.87% compared to Humana's net margin of 10.26%. Humana's return on equity of 10.08% beat Amedisys's return on equity of 7.55%.

    Company Gross Margin Earnings Per Share Invested Capital
    HUM
    Humana
    -- $10.30 $31.1B
    AMED
    Amedisys
    43.84% $1.84 $1.6B
  • What do Analysts Say About HUM or AMED?

    Humana has a consensus price target of $298.53, signalling upside risk potential of 26.82%. On the other hand Amedisys has an analysts' consensus of $97.38 which suggests that it could grow by 0.04%. Given that Humana has higher upside potential than Amedisys, analysts believe Humana is more attractive than Amedisys.

    Company Buy Ratings Hold Ratings Sell Ratings
    HUM
    Humana
    6 17 0
    AMED
    Amedisys
    0 10 1
  • Is HUM or AMED More Risky?

    Humana has a beta of 0.427, which suggesting that the stock is 57.339% less volatile than S&P 500. In comparison Amedisys has a beta of 0.940, suggesting its less volatile than the S&P 500 by 5.975%.

  • Which is a Better Dividend Stock HUM or AMED?

    Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.5%. Amedisys offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humana pays 35.71% of its earnings as a dividend. Amedisys pays out -- of its earnings as a dividend. Humana's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios HUM or AMED?

    Humana quarterly revenues are $32.1B, which are larger than Amedisys quarterly revenues of $594.8M. Humana's net income of $1.2B is higher than Amedisys's net income of $61M. Notably, Humana's price-to-earnings ratio is 16.65x while Amedisys's PE ratio is 35.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.24x versus 1.36x for Amedisys. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HUM
    Humana
    0.24x 16.65x $32.1B $1.2B
    AMED
    Amedisys
    1.36x 35.92x $594.8M $61M
  • Which has Higher Returns HUM or CVS?

    CVS Health has a net margin of 3.87% compared to Humana's net margin of 1.88%. Humana's return on equity of 10.08% beat CVS Health's return on equity of 7%.

    Company Gross Margin Earnings Per Share Invested Capital
    HUM
    Humana
    -- $10.30 $31.1B
    CVS
    CVS Health
    15.22% $1.41 $141.8B
  • What do Analysts Say About HUM or CVS?

    Humana has a consensus price target of $298.53, signalling upside risk potential of 26.82%. On the other hand CVS Health has an analysts' consensus of $79.49 which suggests that it could grow by 17.4%. Given that Humana has higher upside potential than CVS Health, analysts believe Humana is more attractive than CVS Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    HUM
    Humana
    6 17 0
    CVS
    CVS Health
    13 7 0
  • Is HUM or CVS More Risky?

    Humana has a beta of 0.427, which suggesting that the stock is 57.339% less volatile than S&P 500. In comparison CVS Health has a beta of 0.559, suggesting its less volatile than the S&P 500 by 44.102%.

  • Which is a Better Dividend Stock HUM or CVS?

    Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.5%. CVS Health offers a yield of 3.93% to investors and pays a quarterly dividend of $0.67 per share. Humana pays 35.71% of its earnings as a dividend. CVS Health pays out 73.1% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios HUM or CVS?

    Humana quarterly revenues are $32.1B, which are smaller than CVS Health quarterly revenues of $94.6B. Humana's net income of $1.2B is lower than CVS Health's net income of $1.8B. Notably, Humana's price-to-earnings ratio is 16.65x while CVS Health's PE ratio is 16.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.24x versus 0.23x for CVS Health. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HUM
    Humana
    0.24x 16.65x $32.1B $1.2B
    CVS
    CVS Health
    0.23x 16.16x $94.6B $1.8B
  • Which has Higher Returns HUM or OPCH?

    Option Care Health has a net margin of 3.87% compared to Humana's net margin of 3.51%. Humana's return on equity of 10.08% beat Option Care Health's return on equity of 15.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    HUM
    Humana
    -- $10.30 $31.1B
    OPCH
    Option Care Health
    19.73% $0.28 $2.5B
  • What do Analysts Say About HUM or OPCH?

    Humana has a consensus price target of $298.53, signalling upside risk potential of 26.82%. On the other hand Option Care Health has an analysts' consensus of $38.56 which suggests that it could grow by 21.17%. Given that Humana has higher upside potential than Option Care Health, analysts believe Humana is more attractive than Option Care Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    HUM
    Humana
    6 17 0
    OPCH
    Option Care Health
    6 1 0
  • Is HUM or OPCH More Risky?

    Humana has a beta of 0.427, which suggesting that the stock is 57.339% less volatile than S&P 500. In comparison Option Care Health has a beta of 0.741, suggesting its less volatile than the S&P 500 by 25.903%.

  • Which is a Better Dividend Stock HUM or OPCH?

    Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.5%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humana pays 35.71% of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend. Humana's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios HUM or OPCH?

    Humana quarterly revenues are $32.1B, which are larger than Option Care Health quarterly revenues of $1.3B. Humana's net income of $1.2B is higher than Option Care Health's net income of $46.7M. Notably, Humana's price-to-earnings ratio is 16.65x while Option Care Health's PE ratio is 25.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.24x versus 1.05x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HUM
    Humana
    0.24x 16.65x $32.1B $1.2B
    OPCH
    Option Care Health
    1.05x 25.66x $1.3B $46.7M
  • Which has Higher Returns HUM or OPRX?

    OptimizeRx has a net margin of 3.87% compared to Humana's net margin of -10.03%. Humana's return on equity of 10.08% beat OptimizeRx's return on equity of -13.03%.

    Company Gross Margin Earnings Per Share Invested Capital
    HUM
    Humana
    -- $10.30 $31.1B
    OPRX
    OptimizeRx
    60.85% -$0.12 $148.8M
  • What do Analysts Say About HUM or OPRX?

    Humana has a consensus price target of $298.53, signalling upside risk potential of 26.82%. On the other hand OptimizeRx has an analysts' consensus of $15.67 which suggests that it could grow by 13.77%. Given that Humana has higher upside potential than OptimizeRx, analysts believe Humana is more attractive than OptimizeRx.

    Company Buy Ratings Hold Ratings Sell Ratings
    HUM
    Humana
    6 17 0
    OPRX
    OptimizeRx
    4 1 0
  • Is HUM or OPRX More Risky?

    Humana has a beta of 0.427, which suggesting that the stock is 57.339% less volatile than S&P 500. In comparison OptimizeRx has a beta of 1.337, suggesting its more volatile than the S&P 500 by 33.676%.

  • Which is a Better Dividend Stock HUM or OPRX?

    Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.5%. OptimizeRx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humana pays 35.71% of its earnings as a dividend. OptimizeRx pays out -- of its earnings as a dividend. Humana's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios HUM or OPRX?

    Humana quarterly revenues are $32.1B, which are larger than OptimizeRx quarterly revenues of $21.9M. Humana's net income of $1.2B is higher than OptimizeRx's net income of -$2.2M. Notably, Humana's price-to-earnings ratio is 16.65x while OptimizeRx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.24x versus 2.68x for OptimizeRx. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HUM
    Humana
    0.24x 16.65x $32.1B $1.2B
    OPRX
    OptimizeRx
    2.68x -- $21.9M -$2.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Reddit Stock Be In 5 Years?
Where Will Reddit Stock Be In 5 Years?

On a wet March morning last year, the famously orange…

Will Palantir Crash?
Will Palantir Crash?

AI and data analytics software major Palantir (NASDAQ:PLTR) has been…

Is Target’s Dividend Worth Buying?
Is Target’s Dividend Worth Buying?

Retail giant Target (NYSE:TGT) has been through an extremely volatile…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 41x

Buy
60
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 49x

Sell
37
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Sell
49
RGC alert for Jun 17

Regencell Bioscience Holdings [RGC] is up 30.47% over the past day.

Buy
75
ARQQ alert for Jun 17

Arqit Quantum [ARQQ] is up 6.36% over the past day.

Buy
59
SYM alert for Jun 17

Symbotic [SYM] is down 3.91% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock